Literature DB >> 3884475

T lymphocyte sensitization to HBcAg and T cell-mediated unresponsiveness to HBsAg in hepatitis B virus-related chronic liver disease.

S Vento, J E Hegarty, A Alberti, C J O'Brien, G J Alexander, A L Eddleston, R Williams.   

Abstract

Using a newly developed indirect T lymphocyte migration inhibition test, cell-mediated immunity to HBsAg and HBcAg was directly and simultaneously examined in a total of 21 patients with HBsAg-positive chronic liver disease (CLD), and in seven subjects whose sera contained anti-HBs (2 previous acute hepatitis B; 4 hepatitis B vaccine recipients and 1 chronic active hepatitis). T cell sensitization to HBcAg was invariably detected in the HBsAg-positive CLD patients tested (12/12), whereas T cell sensitization to HBsAg was not present in any of the patients (0/21). In contrast, T cell sensitization to HBsAg was present in all anti-HBs-positive subjects. These results support the hypothesis that the cellular immune response to HBcAg, rather than to HBsAg, is implicated in the pathogenesis of HBsAg-positive CLD. Moreover, the observation that the addition of T cells from patients with HBsAg-positive CLD to T cells from anti-HBs positive subjects in a ratio of 1 to 9 reversed their sensitization to HBsAg, suggests that a hyperactivity of HBsAg-specific suppressor T cell population may be responsible for persistent HBs antigenemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3884475     DOI: 10.1002/hep.1840050206

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

Review 1.  Hepatology.

Authors:  P M Harrison; J Y Lau; R Williams
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

Review 2.  Chronic active hepatitis.

Authors:  P J Johnson; I G McFarlane
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 3.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection.

Authors:  T Ehata; M Omata; O Yokosuka; K Hosoda; M Ohto
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

5.  Natural killer activity in patients with chronic hepatitis treated with OK432, interferon, adenine arabinoside and glycyrrhizin.

Authors:  T Wada; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-06

6.  Immunogenicity of peptide fusions to hepatitis B virus core antigen.

Authors:  S J Stahl; K Murray
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  In-vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis.

Authors:  M Mondelli; A Alberti; F Tremolada; R Williams; A L Eddleston; G Realdi
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

8.  Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals.

Authors:  S S Chiou; K Yamauchi; T Nakanishi; H Obata
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

9.  Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection.

Authors:  A J Demetris; R Jaffe; D G Sheahan; J Burnham; J Spero; S Iwatsuki; D H Van Theil; T E Starzl
Journal:  Am J Pathol       Date:  1986-10       Impact factor: 4.307

10.  Glycyrrhizin withdrawal followed by human lymphoblastoid interferon in the treatment of chronic hepatitis B.

Authors:  J Hayashi; W Kajiyama; A Noguchi; K Nakashima; M Hirata; S Hayashi; S Kashiwagi
Journal:  Gastroenterol Jpn       Date:  1991-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.